Tharimmune (NASDAQ:THAR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tharimmune (NASDAQ:THAR) from a sell rating to a hold rating in a research report report published on Sunday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Tharimmune in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Tharimmune presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Tharimmune Stock Performance

Shares of THAR stock opened at $2.93 on Friday. The company has a market capitalization of $22.30 million, a P/E ratio of -0.48 and a beta of 1.41. The company’s 50 day moving average price is $3.56 and its two-hundred day moving average price is $2.19. Tharimmune has a 52 week low of $0.95 and a 52 week high of $9.08.

Tharimmune (NASDAQ:THAR) last announced its earnings results on Thursday, August 14th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.06).

Institutional Trading of Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. XTX Topco Ltd acquired a new stake in Tharimmune, Inc. (NASDAQ:THAR) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 12,911 shares of the company’s stock, valued at approximately $25,000. XTX Topco Ltd owned about 0.31% of Tharimmune as of its most recent SEC filing. 1.16% of the stock is currently owned by institutional investors and hedge funds.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).